Avastin® (bevacizumab) Non-oncology

Covered: Avastin (bevacizumab) is authorized for non‑oncology, compendial ophthalmic uses for neovascular/vascular eye conditions (e.g., diabetic macular edema/retinopathy, RVO‑related macular edema, myopic choroidal neovascularization, neovascular AMD, neovascular glaucoma, retinopathy of prematurity, sickle cell neovascularization, and other choroidal neovascular conditions); oncology indications are excluded. Key requirements: an approved compendial diagnosis, documentation that the patient meets specific coverage and safety criteria, administration by or under the supervision of an ophthalmologist, and authorization/documentation is issued for a 12‑month period with ongoing documentation required for reauthorization.

"Neovascular or vascular ophthalmic conditions (general)"

Sign up to see full coverage criteria, indications, and limitations.